Study: NCT02112097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subcutaneously
Description: Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subcutaneously
Description: Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subcutaneously
Description: Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subcutaneously
Description: Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subcutaneously
Description: Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subcutaneously
Description: Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subcutaneously
Description: Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subdermally at Week 36
Description: Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subdermally at Week 36
Description: Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subdermally at Week 36
Description: Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subdermally at Week 36
Description: Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subdermally at Week 36
Description: Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subdermally at Week 36
Description: Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subdermally at Week 36
Description: Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subdermally at Week 36
Description: Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subdermally at Week 36
Description: Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.